Skip to content

Efficacy of Electrical Pudendal Nerve Stimulation and Sacral Neuromodulation in Treating Non-obstructive Neurogenic Urinary Retention: A Comparative Study

Efficacy of Electrical Pudendal Nerve Stimulation and Sacral Neuromodulation in Treating Non-obstructive Neurogenic Urinary Retention: A Comparative Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200060721
Enrollment
Unknown
Registered
2022-06-09
Start date
2022-06-20
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

uroschesis

Interventions

Group A:electro-acupuncture pudendal nerve stimulation
Group B:sacral neuromodulation

Sponsors

Pudong New Area Gongli Hospital, Naval Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-85 years; 2. According to the European Urological Association neurourology Guidelines 2017, related neurological disorders include: (1) Spinal cord injury (trauma, multiple sclerosis, myelitis, spina bifida); (2) Disc diseases (including cauda equina syndrome); (3) Iatrogenic injury (radical resection of rectal cancer, radical resection of cervical cancer, radical resection of endometrial cancer After pelvic surgery; After pelvic chemotherapy); 3. Non-instrumental obstructive urinary retention followed by the related neurological lesions mentioned above; 4. Upper urinary tract function was normal; 5. Other therapies and drugs that may affect the evaluation of this therapy have been discontinued 2 weeks ago; 6. Voluntarily participate in the study and sign the informed consent; 7. Good compliance, able to meet the requirements of follow-up.

Exclusion criteria

Exclusion criteria: (1) Patients with pons or above neurological lesions or complete spinal cord injury; (2) Pregnant or lactating women; (3) The symptoms can be significantly improved after drug therapy and adjuvant therapy; (4) Complicated with acute or chronic prostatitis, prostate cancer, bladder neck stricture, urethral stricture and urethral damage; (5) Complicated with malignant tumor, serious cardio-cerebrovascular, liver, kidney and other serious life-threatening primary diseases and psychopaths; (6) Patients with obstructive urinary retention; (7) Patients considered unsuitable for this clinical study by the researcher.

Design outcomes

Primary

MeasureTime frame
Residual urine volume;

Secondary

MeasureTime frame
International Urinary Incontinence Association Lower Urinary Tract Symptom Scale;International Urinary Incontinence Association Lower Urinary Tract Quality of Life Scale;

Countries

China

Contacts

Public ContactJianwei Lyu

Pudong New Area Gongli Hospital, Naval Military Medical University

ljwass2020@163.com+86 13816694688

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026